| 浜松ホトニクスが2波長画像を同時に取得可能なデュアルCCDカメラ「ORCA-D2」を開発
November 30, 2009 at 11:00 pm
|
| 浜松--(BUSINESS WIRE)--（ビジネスワイヤ） -- 浜松ホトニクス株式会社（東証：6965）は、取り替え可能な光学ブロックの採用により、実験用途に応じた異なる2ૣ
      
 | Media Files
ViewMedia?mgid=206477&vid=2 (2 KB)
|
| "Carga positiva," una nueva iniciativa para ayudar a derribar barreras y brindar apoyo a las personas que viven con el VIH/SIDA
November 30, 2009 at 6:45 pm
|
| WASHINGTON, D.C.--(BUSINESS WIRE)--El Fondo Nacional del SIDA (NAF, por sus siglas en inglés) y Bristol-Myers Squibb Company (NYSE: BMY) anunciaron hoy su intención de lanzar un nuevo proyecto denominado “Carga positiva.” Esta iniciativa multianual tiene como objeto la implementación de un plan de ayuda tendiente a derribar las barreras que previenen que las personas infectadas con el VIH reciban el cuidado, tratamiento y apoyo necesarios. El lanzamiento de la iniciati
 |
| Idaho Technology's FilmArray™ Receives Military Funding for CLIA Waiver Effort
November 30, 2009 at 5:17 pm
|
| SALT LAKE CITY--(BUSINESS WIRE)--The Defense Threat Agency (DTRA), on behalf of the U.S. Air Force Assistant Surgeon General, Modernization Directorate (AF/SGR), has awarded Idaho Technology, Inc. $3.3 million to advance development of the FilmArray™ system and pursue Clinical Laboratory Improvement Amendments (CLIA) waiver from the Food and Drug Administration (FDA). CLIA waiver applies to tests that are simple to perform and interpret, such as rapid Strep tests and pregnancy tests, and c
 | Media Files
ViewMedia?mgid=177922&vid=2 (2 KB)
|
| Synovis Life Technologies Announces Publication of Veritas® Article in The American Journal of Surgery
November 30, 2009 at 4:05 pm
|
| ST. PAUL, Minn.--(BUSINESS WIRE)--Synovis Life Technologies, Inc. (Nasdaq: SYNO), a leading biomaterial and surgical products company, announced today that The American Journal of Surgery has published an article on the performance of Synovis’ Veritas® Collagen Matrix for the repair of complex ventral hernias. The lead author is Dr. Jonathan N. Limpert, who describes the outcomes of 26 patients who were treated with Veritas for complex ventral hernias. Veritas is an extremely conforma
 |
| Human Genome Sciences Announces Proposed Public Offering of Common Stock
November 30, 2009 at 4:01 pm
|
| ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has commenced an underwritten public offering of up to 12,500,000 shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of the Company’s common stock. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchang
 | Media Files
ViewMedia?mgid=195694&vid=2 (2 KB)
|
| Leipzig accueille EuroMedtechMC 2010
November 30, 2009 at 3:59 pm
|
| ZURICH et LEIPZIG, Allemagne--(BUSINESS WIRE)--Le Groupe EBD annonce aujourd'hui que la seconde conférence annuelle de partenariat EuroMedtech™ aura lieu à l'hôtel Westin de Leipzig, en Allemagne, les 1er et 2 juin 2010. EuroMedtech offre aux investisseurs et aux décideurs du secteur des technologies médicales des possibilités de collaboration sans précédent. EuroMedtech attire en effet des sociétés dans tous les domaines des technologies m
 |
| Leipzig ist Gastgeber der EuroMedtech™ 2010
November 30, 2009 at 3:21 pm
|
| ZÜRICH und LEIPZIG, Deutschland--(BUSINESS WIRE)--Die zweite jährliche Partnerjahreskonferenz EuroMedtech™ findet vom 1. bis 2. Juni 2010 im Westin Hotel in Leipzig statt. Dies hat die EBD Group heute bekannt gegeben. Die EuroMedtech bietet Entscheidungsträgern und Anlegern aus dem Bereich der Medizintechnik einmalige Möglichkeiten zur Zusammenarbeit. Sie zieht Unternehmen aus allen Bereichen der modernen Medizintechnik an, darunter Technologien für Diagnose, Bildgebung
 |
| VELCADE® (Bortezomib) for Injection to be Featured in Plenary Session at American Society of Hematology
November 30, 2009 at 3:19 pm
|
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced nearly 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematology (ASH) being held December 5–8, 2009 in New Orleans, Louisiana. These abstracts include an oral presentation of data on successful VELCADE utilization in both induction and maintenance in the front-line setting during the distinguished plenary session being held on Sunday, December 6. T
 | Media Files
ViewMedia?mgid=179318&vid=2 (2 KB)
|
| Resumen: Leipzig acoge EuroMedtechTM 2010
November 30, 2009 at 1:22 pm
|
| ZURICH & LEIPZIG, Alemania--(BUSINESS WIRE)--EBD Group ha anunciado que el II Congreso anual EuroMedtechTM se celebrará en el hotel The Westin en Leipzig (Alemania), del 1 al 2 de junio, 2010. EuroMedtech ofrece oportunidades sin precedentes para la colaboración entre los directivos del sector de tecnología médica y los inversores. EuroMedtech atrae a empresas de todas las ramas de la industria de la tecnología médica avanzada, incluidas tecnologías de diagn
 |
| Samenvatting: Leipzig ontvangt bijeenkomst EuroMedtech 2010
November 30, 2009 at 1:13 pm
|
| ZURICH & LEIPZIG, Germany--(BUSINESS WIRE)--EBD Group maakt vandaag bekend dat het tweede jaarlijkse partnering congres van EuroMedtech op 1 en 2 juni 2010 zal worden gehouden in het Westin hotel in Leipzig, Duitsland. EuroMedtech biedt ongeëvenaarde kansen voor samenwerking met andere beleidsmakers en beleggers in de medtechwereld. EuroMedtech 2010 brengt wederom beleidsmakers uit alle sectoren van de snel groeiende en sterk innoverende Europese medisch-technologische bedrijfstak bijeen. V
 |
| Riassunto: Lipsia ospiterà l'EuroMedtech™ 2010,
November 30, 2009 at 1:12 pm
|
| ZURIGO & LIPSIA, Germania--(BUSINESS WIRE)--EBD Group ha annunciato oggi che la 2a conferenza annuale per il partnering EuroMedtech™ si terrà presso The Westin Leipzig Hotel a Lipsia, in Germania, l'1 e il 2 giugno 2010. EuroMedtech offre opportunità ineguaguabili di collaborazione tra i responsabili delle decisioni nel campo della tecnologia medica e gli investitori, attirando società operative in tutti i settori della tecnologia medica avanzata, inclusi la diagnostica, l'i
 |
| Research and Markets: Molecular Diagnostics - A World Market Review
November 30, 2009 at 1:00 pm
|
| DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2a9825/molecular_diagnost) has announced the addition of the "Molecular Diagnostics - A World Market Review" report to their offering. Molecular diagnostics market is being driven by several growth factors that include the need for automated and easy-to-handle techniques, which combine optimized sample preparation, analysis, and data evaluation, and the growing availability of molecular diagnostic tests for
 |
| Canon Marketing Japan to Distribute Sectra MicroDose Mammography
November 30, 2009 at 12:39 pm
|
| STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Sectra (STO:SECTB) today announces a partnership agreement with Canon Marketing Japan, Inc., an affiliate of Canon Inc. Canon Marketing Japan is headquartered in Tokyo and has offices in all of the major cities in Japan. The company employs nearly 20,000 people and has annual sales in excess of JPY 800 billion (USD 9 billion). Under this agreement, Canon Marketing Japan will become a distributor of Sectra’s digital mammography system, Sectra Mic
 |
| New Initiative: "Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS
November 30, 2009 at 12:30 pm
|
| WASHINGTON--(BUSINESS WIRE)--The National AIDS Fund (NAF) and Bristol-Myers Squibb Company (NYSE: BMY) announced today their intention to launch “Positive Charge,” a new multiyear initiative aimed at helping to break down the barriers that prevent people living with HIV from receiving HIV care, treatment and necessary support. The initiative is slated to launch in January 2010. “Although we have come a long way in the fight against HIV and AIDS, there are more than a milli
 |
| Resumen: PRA International consigue la acreditación más alta en el programa de Medidata para CRO
November 30, 2009 at 11:20 am
|
| NUEVA YORK y RALEIGH, Carolina del Norte--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), proveedor líder mundial de soluciones de desarrollo clínico alojadas, ha comunicado que PRA International, organización mundial de investigación clínica (CRO), ha conseguido el estatus Rave Accredited Plus en el programa ASPire to Win® para CROs y otros proveedores de servicios. El nivel más alto del programa, Rave Accredited Plus permite a PRA ofrecer de manera indepe
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| Samenvatting: PRA International ontvangt hoogste erkenning in het CRO-programma van Medidata
November 30, 2009 at 11:13 am
|
| NEW YORK and RALEIGH, N.C.--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), een toonaangevende internationale leverancier van klinische testtoepassingen, maakt vandaag bekend dat PRA International de status Rave Accredited Plus heeft gekregen in het programma getiteld ASPire to Win van Medidata. PRA International is een wereldwijd actieve klinische onderzoeksorganisatie. Met de Rave Accredited Plus, de hoogste rang binnen het programma, kan PRA onafhankelijk zijn klanten het hele pakket aan
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| BioMimetic Therapeutics, Inc. to Present at the Piper Jaffray 21st Annual Healthcare Conference
November 30, 2009 at 10:40 am
|
| FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Steven Hirsch, COO and executive vice president of orthopedics, will provide an update of corporate activities at the Piper Jaffray 21st Annual “Unplugged” Healthcare Conference on Wednesday, December 2nd at 1:30 p.m. Eastern Time. The presentation is being held in the Holmes 2 Room at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be availabl
 | Media Files
ViewMedia?mgid=54841&vid=2 (2 KB)
|
| Le prix « Best Change-Maker » a été remis à Orange Business Services et à Sorin Group pour leur solution innovante de suivi à distance de patients cardiaques
November 30, 2009 at 10:07 am
|
| MILAN & PARIS--(BUSINESS WIRE)--Le point d’orgue de la dernière cérémonie annuelle des World Communication Awards (WCA) a été l’attribution du prix du « Best Change Maker » (Meilleur Initiateur de Changement) à Orange Business Services et à Sorin Group, une société leader dans le traitement des maladies cardiovasculaires, pour leurs travaux novateurs dans la mise au point d’une solution de suivi à distance de
 | Media Files
ViewMedia?mgid=66839&vid=2 (2 KB)
|
| Orange Business Services e Sorin Group premiati con il Best Change-Maker per le innovazioni nel monitoraggio medico a distanza e nella telemedicina
November 30, 2009 at 10:07 am
|
| MILANO & PARIGI--(BUSINESS WIRE)--Protagonisti di spicco all’annuale World Communication Awards (WCA) di quest’anno sono stati Orange Business Services e Sorin Group, leader globale nel trattamento delle malattie cardiovascolari, nominati “Best Change-Maker” per gli innovativi risultati ottenuti nello sviluppo di soluzioni di monitoraggio medico a distanza per i pazienti cardiaci. Il premio conferito dalla WCA è il riconoscimento più prestigioso nel settore dell
 | Media Files
ViewMedia?mgid=66839&vid=2 (2 KB)
|
| Biomagnetics Signs Contract With Los Alamos National Security
November 30, 2009 at 10:00 am
|
| SAN FRANCISCO--(BUSINESS WIRE)--Biomagnetics Diagnostics Corp. (PINK SHEETS:BMGP), a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the Company has finalized a "Patent License Agreement with Los Alamos National Security." Under the agreement, Biomagnetics will have access to the Triggered Optical Biosensor and Integrated Optical Biosensor System (IBOS) technology, developed at Los Alamos National Laboratory. IO
 |
| Orange Business Services and Sorin Group Awarded Best Change-Maker for Innovations in Remote Health Monitoring and Telemedicine
November 30, 2009 at 9:54 am
|
| MILAN & PARIS--(BUSINESS WIRE)--A highlight at this year’s annual World Communication Awards (WCA) was Orange Business Services, and Sorin Group, a global leader in the treatment of cardiovascular diseases, being named "Best Change-Maker” for their innovative work in the development of a remote monitoring solution for cardiac patients. The Best Change Maker Award from WCA is the telecommunications industry’s most prestigious prize for monumental business achievements. The remot
 | Media Files
ViewMedia?mgid=66839&vid=2 (2 KB)
|
| Claresa Levetan MD, Co-Founder, CureDM, Inc., Selected for the Class of 2009 Women of Distinction by Philadelphia Business Journal
November 30, 2009 at 9:50 am
|
| WYNNEWOOD, Pa.--(BUSINESS WIRE)--Dr. Claresa Levetan, a co-founder of CureDM, Inc., www.CureDM.com, was named as a 2009 Business Woman of Distinction by the Philadelphia Business Journal and National Association of Women Business Owners. CureDM is a biopharmaceutical company dedicated to developing novel therapeutic approaches to diabetes. Dr. Levetan is recognized for her commitment to science, business and community involvement. “I am extremely proud to have been selected for such a pres
 | Media Files
ViewMedia?mgid=206425&vid=2 (2 KB)
|
| PPD Completes Acquisition of BioDuro
November 30, 2009 at 9:27 am
|
| WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today announced it has completed its acquisition of BioDuro LLC, a drug discovery outsourcing company focused on integrated drug discovery programs and services. With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China, making it the largest contract research organization to offer clinical development and discovery services in the country. “Our acquisition of BioDuro positions us to c
 | Media Files
ViewMedia?mgid=130407&vid=2 (2 KB)
|
| Leipzig to Play Host to EuroMedtech™ 2010
November 30, 2009 at 9:16 am
|
| ZURICH & LEIPZIG, Germany--(BUSINESS WIRE)--EBD Group today announced that the 2nd annual EuroMedtech™ partnering conference will be held at The Westin hotel in Leipzig, Germany, on June 1–2, 2010. EuroMedtech provides unparalleled opportunities for collaboration among medtech decision makers and investors. EuroMedtech attracts companies from all parts of the advanced medical technology industry, including diagnostics, imaging, orthopedics, cardiovascular, biomaterials and eHealth te
 |
| Sunshine Biopharma, Inc. Announces New Trading Symbol
November 30, 2009 at 9:00 am
|
| MONTREAL--(BUSINESS WIRE)--Sunshine Biopharma, Inc., (OTCBB: MWBN) today announced that the trading symbol for its common stock has changed to “SBFM”effective immediately. Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Difluoro-Etoposide™, is a multi-purpose anti-tumor compound that is expected to enter Phase I clinical trials in C
 |
| Terapio Secures $5 million in Series A Financing from Santé Ventures
November 30, 2009 at 9:00 am
|
| AUSTIN, Texas--(BUSINESS WIRE)--Terapio Corporation, a development stage biotechnology company based in Austin, Texas, today announced it has secured $5 million in equity financing from Santé Ventures. Terapio is developing a pipeline of therapeutic applications based on the unique properties RLIP76, a transport protein that helps move large molecules across the cell membrane. The first application of Terapio’s technology is as a radiation countermeasure, which has been demonstrated b
 | Media Files
ViewMedia?mgid=206467&vid=2 (2 KB)
|
| Inovio Partner Announces Completion of Phase I DNA Vaccine Study
November 30, 2009 at 9:00 am
|
| SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology. The study established the safety and tolerability of this therapy, with vaccine-induced immune responses and transient effects on the serum levels of hepatitis C viru
 | Media Files
ViewMedia?mgid=42777&vid=2 (2 KB)
|
| Depomed Files Patent Infringement Lawsuit Against Lupin Limited
November 30, 2009 at 9:00 am
|
| MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (Nasdaq:DEPO) today announced that it has filed a lawsuit in the United States District Court for the Northern District of California against Lupin Limited and its wholly-owned subsidiary, Lupin Pharmaceuticals, Inc., for infringement of the patents listed in the Orange Book for GLUMETZA® (metformin hydrochloride extended release tablets). The lawsuit is in response to an Abbreviated New Drug Application (ANDA) filed by Lupin with the U.S.
 |
| TargetRx Introduces New Research Capability to Increase Effectiveness of Co-Pay Card Initiatives
November 30, 2009 at 9:00 am
|
| HORSHAM, Pa.--(BUSINESS WIRE)--Companies marketing branded pharmaceuticals are facing an increasing need to make products more accessible and affordable for patients. Furthermore, the rise of competition among branded drugs has led many pharmaceutical companies to focus less on DTC spending and more on increased investment in co-pay card programs in order to make these treatments more cost-effective for patients. In response to this market demand, TargetRx today announced a new offering that ena
 | Media Files
ViewMedia?mgid=43986&vid=2 (2 KB)
|
| Emisphere Technologies Announces Extension of Maturity Date for Novartis Convertible Promissory Note
November 30, 2009 at 8:45 am
|
| CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to extend the maturity date of Emisphere’s Convertible Promissory Note (the “Note”) to February 26, 2010. The $10 million original principal amount Note, plus interest accrued to date
 |
| MagForce Nanotechnologies AG Applies for European Regulatory Approval of Its Nano-Cancer® Therapy
November 30, 2009 at 8:30 am
|
| BERLIN--(BUSINESS WIRE)--MagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products. With this step, MagForce has now commenced the conformity assessment procedure for its Nano-Cancer ® therapy. Following successful completion of this conformity assessment procedure and EC type testing of the magnetic field applicator, MagForce will be a
 | Media Files
ViewMedia?mgid=198147&vid=2 (2 KB)
|
| PRAインターナショナルがメディデータ・ソリューションズのCRO向けプログラムで 最高レベルの認定を取得
November 30, 2009 at 8:30 am
|
| NEW YORK & RALEIGH, N.C.--(BUSINESS WIRE)--ホスト型臨床開発ソリューションのリーディング・グローバル・プロバイダである メディデータ・ソリューションズ（NASDAQ: MDSO）は
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| Riassunto: PRA International raggiunge il riconoscimento più elevato nel programma CRO di Medidata
November 30, 2009 at 8:30 am
|
| NEW YORK e RALEIGH, North Carolina--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), uno dei più importanti fornitori globali di soluzioni ospitate di sviluppo clinico, ha annunciato oggi che PRA International, un'organizzazione di ricerche cliniche (CRO) globale, ha raggiunto la categoria Rave Accredited Plus nel programma ASPire to Win® per CRO e altri fornitori di servizi. Essendo l'ordine massimo raggiungibile nel programma, la categoria Rave Accredited Plus consente a PRA Inter
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| PRA International obtient la plus haute accréditation dans le programme de Medidata pour les CRO
November 30, 2009 at 8:30 am
|
| NEW YORK et RALEIGH, Caroline du Nord--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), un fournisseur mondial de premier plan de solutions hébergées de développement clinique, a annoncé aujourd'hui que PRA International, un organisme de recherche clinique (CRO) mondial, avait obtenu l’accréditation Rave Accredited Plus dans le programme ASPire to Win® pour les CRO et les autres fournisseurs de services. Le niveau le plus élevé du programme, Rave
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| PRA International erhält höchste Akkreditierung im Rahmen des CRO-Programms von Medidata
November 30, 2009 at 8:30 am
|
| NEW YORK und RALEIGH, North Carolina--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), ein führender, weltweit tätiger Anbieter von gehosteten Lösungen für die klinische Entwicklung, teilte heute mit, dass PRA International, ein globales Auftragsforschungsinstitut (CRO), den Status Rave Accredited Plus im Rahmen des ASPire-to-Win®-Programms für CROs und andere Dienstleistungsanbieter erhalten hat. Rave Accredited Plus, die höchste Stufe des Programms, erm
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| PRA International Achieves Highest Accreditation in Medidata CRO Program
November 30, 2009 at 8:30 am
|
| NEW YORK and RALEIGH, N.C.--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that PRA International, a global clinical research organization (CRO), has achieved Rave Accredited Plus status in the ASPire to Win® program for CROs and other service providers. The highest achievable tier in the program, Rave Accredited Plus enables PRA to independently offer its customers a full suite of services around the M
 | Media Files
ViewMedia?mgid=47691&vid=2 (2 KB)
|
| Memorial Medical Center Chooses ProVation® Order Sets, powered by UpToDate® Decision Support
November 30, 2009 at 8:30 am
|
| MINNEAPOLIS--(BUSINESS WIRE)--Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Memorial Medical Center has selected ProVation® Order Sets, powered by UpToDate® Decision Support, to automate the creation, maintenance and system-wide deployment of evidence-based order sets. Located in Springfield, IL, Memorial Medical Center is a 600-bed acute care, community-based, not-for-profit facility that is also the tea
 | Media Files
ViewMedia?mgid=130457&vid=2 (2 KB)
|
| Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
November 30, 2009 at 8:00 am
|
| WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025. Allos holds an exclusive worldwide license from these institutions to develop a
 | Media Files
ViewMedia?mgid=195346&vid=2 (2 KB)
|
| Xencor Licenses Antibody Optimization Technology
November 30, 2009 at 8:00 am
|
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. (“Centocor”) for the optimization of Centocor’s antibody drug candidates. The license follows a 2009 license agreement that gave Centocor access to Xencor’s proprietary Immunofilte
 | Media Files
ViewMedia?mgid=102409&vid=2 (2 KB)
|
| Emergent Health Corp. (EMGE) Reports Further Progress
November 30, 2009 at 8:00 am
|
| KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Emergent Health Corp. (Other OTC: EMGE) Emergent (the “Company”) is pleased to report approximately 90% revenue growth for the first three quarters of 2009 ($160,101.90) compared to the first three quarters of 2008 ($83,400.40). Projected earnings per share for the three quarters before income taxes are $40,108.15 (25% of revenue) or $0.002 per share. The Company believes up to 25% profitability could be ongoing with revenue growth. The Company
 |
| ReSearch Pharmaceutical Services, Inc. (RPS) Establishes Global Platform to Capitalize on Outsourced Clinical Trials
November 30, 2009 at 8:00 am
|
| FORT WASHINGTON, Pa.--(BUSINESS WIRE)--ReSearch Pharmaceutical Services, Inc. (RPS), a next generation contract research organization (CRO) and provider of integrated clinical development outsourcing solutions, today announced the completion of its global platform to provide advanced integrated CRO services across four continents. RPS has positioned itself to capitalize on the growth of global clinical trials. PharmaVoice reported that up to 65% of FDA-regulated clinical trials in the next three
 |
| Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses When the Vaccine is Delivered by Electrical Impulses
November 30, 2009 at 8:00 am
|
| NEW YORK & SAN DIEGO--(BUSINESS WIRE)--A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City. The results show that TriGrid™, a technology developed by Ichor Medical Systems, Inc., helped to enhance the immunogenicity of the vaccine tested. Compared to intramuscular injection, the conventional mode o
 | Media Files
ViewMedia?mgid=145446&vid=2 (2 KB)
|
| Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
November 30, 2009 at 7:30 am
|
| ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conferences during the months of December 2009 and January 2010. The J.P. Morgan SMid Cap Conference 2009New York, NY.December 3, 2009Presentation Time: 2:15 PM Eastern The J.P. Morgan 28th Annual Healthcare Conference 2010San Francisco, CA.January 11, 2010Presentation Time: 4:30 PM Pacific During each presentation, a member of the
 | Media Files
ViewMedia?mgid=104446&vid=2 (2 KB)
|
| Three Lou Gehrig's Disease (ALS) Organizations Grant Funding for Research Collaboration Between RXi Pharmaceuticals and UMass Medical School
November 30, 2009 at 7:00 am
|
| WORCESTER, Mass.--(BUSINESS WIRE)--Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).
 | Media Files
ViewMedia?mgid=124005&vid=2 (2 KB)
|
| Gentium Reports Third Quarter Financial Results; Provides Financial Update
November 30, 2009 at 7:00 am
|
| VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Gentium S.p.A. (NASDAQ: GENT) (the “Company”) today reported financial results for the quarter ended September 30, 2009. Financial Highlights Gentium S.p.A., or the Company, reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP). The Company’s financial statements are prepared using the Euro (€) as its functional currency. On September 30, 2009, €1.00 = $1.4643. F
 |
|
没有评论:
发表评论